N/A
Completed N=15
Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva
Dry Mouth
Source: ClinicalTrials.gov NCT01690052 ↗
Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Aug 2014
Primary outcomePrimary: Change From Baseline in Saliva Production in ml. — 1.41; 3.93; 5.31; 10.34 ml — p=0.05
Summary
The main objectives were: 1) To determine the efficacy of both cevimeline and pilocarpine in the secretion of saliva in patients with xerostomia, and 2) To compare the side-effects between the treatment for xerostomia with cevimeline and with pilocarpine.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Saliva Production in ml. |
1.41; 3.93; 5.31; 10.34 | 0.05 |
Eligibility Criteria
Potential candidates with the diagnosis of moderate-severe xerostomia were identified from the Oral Medicine Clinic at the University Of Kentucky College Of Dentistry, or self referrals in response to IRB approved study announcements. Enrollment required no clinical evidence of oral lesions, subjective perception of dry mouth and less than 2 mL of saliva collected in 5 minutes without stimulation. Exclusion criteria included patients with non controlled chronic obstructive pulmonary disease (COPD), depression, asthma, cardiac arrhythmias, glaucoma, and the current use of any medication with interactions with cevimeline and pilocarpine.
Data sourced from ClinicalTrials.gov (NCT01690052). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.